Stanley J Wiegand
Inventor
Stats
- 15 US patents issued
- 25 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 15 US Patents Issued
- 25 US Applications Filed
- 320 Total Citation Count
- Dec 28, 2018 Most Recent Filing
- May 13, 1996 Earliest Filing
Work History
| Patent Owner | Applications Filed | Year |
|---|---|---|
| THE JOHNS HOPKINS UNIVERSITY | 1
2 | 2002
2005 |
| REGENERON PHARMACEUTICALS, INC. | 1
1 1 1 3 4 9 2 5 2 2 3 1 | 1996
1998 1999 2001 2002 2004 2005 2006 2007 2014 2015 2016 2017 |
Inventor Addresses
| Address | Duration |
|---|---|
| Croton on Hudson, NY | Dec 04, 07 - Dec 11, 07 |
| Croton on Hudson, NY, US | Aug 11, 05 - Nov 24, 05 |
| Croton-on Hudson, NY | Apr 10, 08 - Apr 10, 08 |
| Croton-on-Hudson, NY | Feb 27, 03 - Sep 11, 08 |
| Croton-on-Hudson, NY, US | Jul 31, 03 - Apr 21, 09 |
| Croton-on-hudson, NY, US | May 12, 09 - May 12, 09 |
| Hopewell Junction, NY, US | Jul 10, 14 - Jul 27, 21 |
| Ossining, NY | Jun 25, 02 - Jan 20, 04 |
Technology Profile
| Technology | Matters | |
|---|---|---|
| A01K: | ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS | 1 |
| A01N: | PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF | 1 |
| A61K: | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | 24 |
Patents / Publication
| Patents / Publication # | Year of Publication / Issued | Title | Citations |
|---|---|---|---|
| 11071780 | 2021 | Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab | 0 |
| 2019/0117,767 | 2019 | METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES | 4 |
| 10023642 | 2018 | Anti-PDGFR-beta antibodies and uses thereof | 0 |
| 2017/0210,813 | 2017 | ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF | 0 |
| 9650444 | 2017 | Anti-PDGFR-beta antibodies and uses thereof | 1 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.